- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT01157923
MD Logic Pump Advisor- Adults Study
Evaluation of Automated Insulin Pump Settings Using the MD-Logic Pump Advisor-Adults Sub Study
Prospective, randomized, controlled, 30-78 days trial comparing MD-Logic pump algorithm to the standard of care of patients with type 1 diabetes.
The objective of this feasibility study is to evaluate the efficacy and safety of automated determined Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) using the MD-Logic Pump Advisor in individuals with type 1 diabetes.The study will be consisted from two segments:(I)pilot study, 30-78 days trial evaluating the MD-Logic pump advisor and (II)randomized controlled 30-78 days trial comparing MD-Logic pump algorithm to the standard of care.In segment 1, the pilot study, the aim is to enroll 15-30 subjects without control group. In segment 2, the randomized controlled segment, the aim is to enroll 92 subjects, but enrolling up to 105 eligible subjects to allow for dropouts.
The randomized controled study segment will be initiated after the pilot segment.Each segment of the study will consist of 6 clinic visits taking place at intervals of 1-3 weeks, sum of 30-78 days study duration for each segment. Before each clinic visit, subjects will wear continuous glucose sensors for 6 days; the intervention group will have up to 4 iterations (e.g the pump setting will be reviewed and adjusted up to 4 times during the study period according to the MD-Logic Pump Advisor).For the control group (at segment 2 only), insulin pump settings will not be changed during the study period (patient's usual standard of care).
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Részletes leírás
the MD-Logic Pump Advisor was design by the Diabetes Technology Center, the Institute of Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel. The MD-Logic Pump Advisor learns and adapts the patient's insulin pump settings in order to optimize glucose control. The MD-Logic Pump Advisor needs, as input, sensor readings, insulin delivery and recording of the meals during home care. During collection of the data, the patients are asked to continue their daily routine (no need for special consideration).
The present study was designed to test the automatic algorithm that will evaluate and change, when necessary, the patient's insulin pump settings based on prior sensor reading, insulin delivery, and meals data that was collected while the patient is under his regular treatment at home.
The objective of this feasibility study is to evaluate the efficacy and safety of automated determined Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) using the MD-Logic Pump Advisor in individuals with type 1 diabetes.
The study will be consisted from two segments:(I)pilot study, 30-78 days trial evaluating the MD-Logic pump advisor and (II)randomized controlled 30-78 days trial comparing MD-Logic pump algorithm to the standard of care.In segment 1, the pilot study, the aim is to enroll 15-30 subjects without control group. In segment 2, the randomized controlled segment, the aim is to enroll 92 subjects, but enrolling up to 105 eligible subjects to allow for dropouts.
The randomized controled study segment will be initiated after the pilot segment.Each segment of the study will consist of 6 clinic visits taking place at intervals of 1-3 weeks, sum of 30-78 days study duration for each segment. Before each clinic visit, subjects will wear continuous glucose sensors for 6 days; the intervention group will have up to 4 iterations (e.g the pump setting will be reviewed and adjusted up to 4 times during the study period according to the MD-Logic Pump Advisor).For the control group (at segment 2 only), insulin pump settings will not be changed during the study period (patient's usual standard of care).
Endpoints:
- Primary endpoint Increase in time spent in the normal range, defined as sensor glucose level within 70 to 180 mg/dl
- Secondary endpoints Reduced time spent above 180 mg/dl, reduced time spent below 70 mg/dl, reduced number of hypoglycemic events below 63 mg/dl, reduced glucose variability, quality of life measurements and subject treatment satisfaction.
Inclusion Criteria:
- Subject with Type 1 diabetes (>1yr since diagnosis)
- Medtronic ( MiniMed Paradigm 522, 512 , 722 or 712) insulin infusion pump CSII (continuous subcutaneous insulin infusion) therapy for at least 3 months
- Age ≥ 18 years
- HbA1c at inclusion ≥ 6.0%
- No concomitant diseases that influence metabolic control
- No current use of CGM
- Subjects do not participate in any other interventional study
Tanulmány típusa
Beiratkozás (Tényleges)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Subject with Type 1 diabetes (>1yr since diagnosis)
- Medtronic( MiniMed Paradigm 522, 512 , 722 or 712) insulin infusion pump CSII therapy for at least 3 months
- Age ≥ 18 years
- HbA1c at inclusion ≥ 6.0%
- No concomitant diseases that influence metabolic control
- No current use of CGM
- Subjects do not participate in any other interventional study
Exclusion Criteria:
- Known or suspected allergy to trial products.
- Any significant diseases or conditions including psychiatric disorders and substance abuse that, in the opinion of the investigator, is likely to affect the subject's ability to complete the study, or compromise patient safety
- Subject is currently using CGM device
- Diabetic ketoacidosis in the past 3 months.
- Severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrollment.
- Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study.
- Subject is participating in another drug or device study that could affect glucose measurements or glucose management.
- Female subject who is pregnant or planning to become pregnant within the planned study duration
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: intervantion group
Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor.
|
Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
|
Nincs beavatkozás: control group
Regular treatment, No change will be made in the insulin pump setting during the study(unless there is a medical need or any safety concern).
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Time spent in the normal range
Időkeret: during each 6 days iteration
|
increase in the time spent in the normal range, defined as sensor glucose level within 70-180 mg/dl
|
during each 6 days iteration
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
number of iterations required to achieve the maximal meaningful improvement in the primary outcome
Időkeret: Day 78
|
number of iterations required to achieve the maximal meaningful improvement in the primary outcome
|
Day 78
|
time spent above 180 mg/dl
Időkeret: during each 6 days iteration
|
time spent above 180 mg/dl
|
during each 6 days iteration
|
time spent below 70 mg/dl
Időkeret: during each 6 days iteration
|
time spent below 70 mg/dl
|
during each 6 days iteration
|
Number of Hypoglycemic events below 63 mg/dl
Időkeret: during each 6 days iteration
|
Number of Hypoglycemic events below 63 mg/dl
|
during each 6 days iteration
|
Adverse event
Időkeret: during each 6 days iteration
|
Adverse event
|
during each 6 days iteration
|
glucose variability- area under the curve
Időkeret: during each 6 days iteration
|
glucose variability measured as area under the curve (the area between the measured blood glucose and the glucose level of 180 mg/dl) and area above the curve (the area between the measured blood glucose and the glucose level of 70 mg/dl
|
during each 6 days iteration
|
Quality of Life Questionaires
Időkeret: At the end of the study- day 30 -78
|
Quality of Life Questionaires
|
At the end of the study- day 30 -78
|
Number of MDLAP-recommendations that were rejected by the physician
Időkeret: during each 6 days iteration
|
Number of MDLAP-recommendations that were rejected by the physician
|
during each 6 days iteration
|
Number and type of changes in any pump setting per iteration
Időkeret: during each 6 days iteration
|
Number and type of changes in any pump setting per iteration
|
during each 6 days iteration
|
Együttműködők és nyomozók
Szponzor
Együttműködők
Nyomozók
- Kutatásvezető: Moshe Phillip, Prof, Schenider Children's Medical
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete
Elsődleges befejezés (Tényleges)
A tanulmány befejezése (Tényleges)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Becslés)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Becslés)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- rmc005816ctil
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a 1-es típusú cukorbetegség
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustMég nincs toborzás
-
Ain Shams Maternity HospitalToborzásRossz válasz az ovulációs indukcióra Poseidon Type IVEgyiptom
-
Merz Pharmaceuticals GmbHLLC Merz Pharma, RussiaBefejezveNői mintás hajhullás | Androgenetikus alopecia (AGA) | Ludwig 1. típus | Ludwig Type 2Orosz Föderáció
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.BefejezveDiabetes mellitus, 1. típusú | 1-es típusú cukorbetegség | 1 típusú cukorbetegség | 1-es típusú diabetes mellitus | Autoimmun cukorbetegség | Diabetes mellitus, inzulinfüggő | Fiatalkorban kezdődő cukorbetegség | Cukorbetegség, Autoimmun | Inzulinfüggő diabetes mellitus 1 | Diabetes mellitus, inzulinfüggő... és egyéb feltételekEgyesült Államok
-
University of California, San FranciscoJuvenile Diabetes Research FoundationBefejezve1-es típusú diabetes mellitus | Diabetes mellitus, I-es típusú | Inzulinfüggő diabetes mellitus 1 | Diabetes mellitus, inzulinfüggő, 1 | IDDMEgyesült Államok, Ausztrália
-
Capillary Biomedical, Inc.BefejezveDiabetes mellitus, 1. típusú | 1-es típusú cukorbetegség | 1-es típusú diabetes mellitus | Diabetes mellitus, inzulinfüggő, 1Ausztrália
-
Galderma R&DBefejezvePlaque-type PsoriasisEgyesült Államok
-
Deltanoid PharmaceuticalsBefejezvePlaque-type PsoriasisEgyesült Államok
-
Capillary Biomedical, Inc.Megszűnt1-es típusú cukorbetegség | 1-es típusú diabetes mellitus | Diabetes mellitus, I-es típusú | Diabetes mellitus, inzulinfüggő, 1 | IDDMAusztria
-
PfizerBefejezveA plakkos típusú pikkelysömör kezelésére szolgáló kenőcs biztonságossági vizsgálata (AN2728-PSR-104)Plaque-type PsoriasisAusztrália
Klinikai vizsgálatok a MD Logic Pump Advisor
-
Rabin Medical CenterMedtronicBefejezve
-
Rabin Medical CenterNovo Nordisk A/S; DreaMedMegszűnt
-
Rabin Medical CenterGIFVisszavont1-es típusú cukorbetegségNémetország, Izrael
-
Rabin Medical CenterVisszavont
-
Rabin Medical CenterBefejezve
-
Rabin Medical CenterBefejezve1-es típusú cukorbetegségIzrael, Németország, Szlovénia
-
Kinderkrankenhaus auf der BultBefejezve